Know Cancer

forgot password

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

Phase 1/Phase 2
70 Years
Open (Enrolling)
Systemic Scleroderma, Severe Systemic Sclerosis

Thank you

Trial Information

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis


I. To determine the safety and potential efficacy of reduced intensity conditioning with
fludarabine/cyclophosphamide/low-dose total body irradiation (TBI) and allogeneic
hematopoietic cell transplantation (HCT) for the stabilization or regression of disease
manifestations of severe systemic sclerosis (SSc).


I. To determine whether stable allogeneic donor engraftment can be safely established with
reduced intensity conditioning followed by matched sibling or unrelated donor bone marrow
transplantation in patients with severe SSc.


Patients receive fludarabine phosphate intravenously (IV) on days -6, -5, -4, -3 and -2 and
Cyclophosphamide IV on days -6, -5, and undergo 2 Gray TBI on day -1. Patients receive human
leukocyte antigen (HLA)-matched donor bone marrow transplantation on day 0. Patients then
receive cyclophosphamide IV on days +3 and +4, and beginning day +5 they start tacrolimus
orally (PO) and enteric coated mycophenolic acid.

After completion of initial study treatment, patients are followed up at 6 months and then
annually for 5 years.

Inclusion Criteria:

- Patients eligible for the study must have a human leukocyte antigen (HLA)-identical
sibling or HLA-matched unrelated bone marrow donor available and willing to donate.

- Patients with severe SSc as defined by the American College of Rheumatology and at
high-risk for a fatal outcome based on the following prognostic factors in groups

- Group 1: Patients must have 1) both a and b below; and 2) at least one of c, d or e:

- a. diffuse cutaneous scleroderma with skin score of greater than or equal to 16
(modified Rodnan scale [mRSS]).

- b. duration of systemic sclerosis less than or equal to 7 years from the onset
of first non-Raynaud's symptom.

- c. presence of interstitial lung disease (either forced vital capacity [FVC] or
corrected diffusing capacity of the lung for carbon monoxide [DLCOcorr] less
than 70 % of predicted) and evidence of alveolitis (abnormal bronchoalveolar
lavage (BAL) or high resolution chest computed tomography [CT] scan) after
treatment with intravenous cyclophosphamide greater than or equal 2 grams given
over at least a 3 month period; for patients not able to adequately complete
pulmonary function tests (PFT), there must be evidence of progressive disease on
chest CT.

- d. left heart failure with left ventricular ejection fraction (LVEF) < 50% (that
has responded to treatment targeted to scleroderma); 2nd or 3rd atrioventricular
(AV) block with other evidence of cardiomyopathy related to SSc; myocardial
disease not secondary to SSc must be excluded by a cardiologist.

- e. history of SSc-related renal disease that is not active at the time of
screening; history of scleroderma hypertensive renal crisis is included in this

- Group 2: Progressive pulmonary disease as defined by a decrease in the FVC or
DLCOcorr by 15 percent or greater compared to a prior FVC or DLCOcorr in the previous
twelve month period; in addition, patients may have either less skin involvement than
group 1 (mRSS less than 16) and the FVC or DLCOcorr is less than 70% or both FVC and
DLCOcorr greater than or equal to 70% if they have diffuse cutaneous disease (mRSS
greater than 16) at screening for the study; patients must also have evidence of
alveolitis as defined by abnormal chest CT or BAL; for patients not able to
adequately complete PFT, there must be evidence of progressive disease on chest CT.

- Group 3: Have progressive active SSc after prior autologous transplant based on the
presence of progressive pulmonary disease; this will be defined by a decrease in the
FVC or DLCO adjusted since prior autologous transplant of 15 percent or greater of
the pre-transplant percent predicted value, in addition to evidence of alveolitis as
defined by chest CT changes or BAL. If patients had prior autologous HCT on the
"Scleroderma: Cyclophosphamide Or Transplantation" (SCOT) clinical trial, they must
have failed based on the defined study endpoints and be approved by the protocol
principal investigator (PI).

- Group 4: Patients who meet group 1 inclusion criteria but may have FVC or
DLCO-adjusted less than 70% plus have had an adverse event on cyclophosphamide
preventing its further use (specifically hemorrhagic cystitis, leukopenia with white
blood cell [WBC]< 2000 or absolute neutrophil count [ANC] < 1000 or platelet count <

- Group 5: Diffuse scleroderma with disease duration less than or equal to 2 years
since development of first sign of skin thickening plus modified Rodnan skin score
greater than or equal to 25 plus erythrocyte sedimentation rate (ESR) > 25 mm/1st
hour and/or hemoglobin (Hb) < 11 g/dL, not explained by causes other than active

- Unless patients have a DLCO-adjusted less than 45%, patients in all groups must have
failed either oral or intravenous cyclophosphamide regimen defined as: IV
cyclophosphamide administration for at least > 3 months between first and last
cyclophosphamide dose at a total cumulative IV dose of at least 2 grams, oral
cyclophosphamide administration for > 4 months regardless of dose, or combination of
oral and IV cyclophosphamide for at least > 6 months independent of dose.

- DONOR: HLA genotypically identical sibling or unrelated donor; unrelated donors are
required to be matched by standard molecular methods at the intermediate resolution
level at HLA-A, B, C and DRB1 and the allele level at DQB1.

- DONOR: Donors must meet the selection criteria as defined by the Foundation for the
Accreditation of Cell Therapy (FACT) and will be screened per the American
Association of Blood Banks (AABB) guidelines

- DONOR: Bone marrow is the preferred cell source

Exclusion Criteria:

- Fertile men or women unwilling to use contraceptive techniques during and for 12
months following transplant

- Evidence of ongoing active infection

- Pregnancy

- Patients with a creatinine clearance < 60 ml/min/1.73 m^2 body surface area

- Uncontrolled clinically significant arrhythmias

- Clinical evidence of significant congestive heart failure (CHF) (New York Heart
Association [NYHA] Class III or IV)

- LVEF < 45% by echocardiogram

- Severe pulmonary dysfunction with a hemoglobin corrected DLCO < 30% or FVC < 40% of
predicted or O2 saturation < 92% at rest without supplemental oxygen

- Significant uncontrolled pulmonary hypertension defined as: Pulmonary artery peak
systolic pressure > 55 mmHg by echocardiogram, or pulmonary artery peak systolic
pressure 45-55 mmHg by echocardiogram and mean pulmonary artery pressure by right
heart catheterization exceeding 25 mmHg at rest (or 30 mmHg with exercise); or
NYHA/World Health Organization (WHO), Class III or IV

- Active hepatitis or liver biopsy evidence of cirrhosis or periportal fibrosis; liver
function tests: total bilirubin > 2 x the upper limit of normal and/or serum glutamic
pyruvate transaminase (SGPT) and SGPT > 4 x the upper limit of normal

- Patients with poorly controlled hypertension

- Patients whose life expectancy is severely limited by illness other than autoimmune

- Patients with poorly controlled bleeding from gastric antral vascular ectasia (GAVE)
or other gastrointestinal (GI) sites

- Untreated psychiatric illness, drug/alcohol abuse

- Inability to give voluntary informed consent or guardian's informed consent

- Demonstrated lack of compliance with prior medical care

- Malignancy within the 2 years prior to treatment, excluding adequately treated
squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ; treatment
must have been completed (with the exception of hormonal therapy for breast cancer)
with cure/remission status verified for at least 2 years at time of treatment

- Human immunodeficiency virus (HIV) seropositivity

- DONOR: Identical twin

- DONOR: Current pregnancy

- DONOR: HIV seropositivity

- DONOR: Deemed medically unable to undergo bone marrow harvesting

- DONOR: Current serious systemic illness including uncontrolled infections

- DONOR: Failure to meet institutional criteria for donation as described in the
Standard Practice Guidelines

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Event-free survival (EFS)

Outcome Description:

The events will be defined as any one of the following: death; respiratory failure; renal failure, as defined by chronic dialysis > or = 6 months or kidney transplantation; occurrence of cardiomyopathy, confirmed by clinical CHF (New York Class III or IV) or LVEF < 30% by echocardiogram, sustained for at least 3 months despite therapy; organ dysfunction specific events must be documented on at least two occasions > or = 3 months apart, or sustained for a 3-month period (documented from the first occurrence).

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

George Georges

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium


United States: Federal Government

Study ID:




Start Date:

September 2006

Completion Date:

Related Keywords:

  • Systemic Scleroderma
  • Severe Systemic Sclerosis
  • scleroderma
  • systemic sclerosis
  • Scleroderma, Systemic
  • Scleroderma, Diffuse
  • Sclerosis



Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington  98109
Colorado Blood Cancer Institute Denver, Colorado  80218